Food and Drug Administration (FDA) under the brand names Ozempic and Rybelsus for managing type 2 diabetes, and as Wegovy for the treatment of excess weight (overweight) and obesity
Financing options are available
The elucidation of various cellular mechanisms linking inflammation with insulin resistance and -cell dysfunction has revolutionised knowledge about the molecular pathogenesis of T2DM, currently establishing that this entity is a metabolic and inflammatory disorder ( Finally, our findings showed a clear anti-inflammatory effect of semaglutide when compared to placebo, but also when compared to other anti-diabetic drugs with proven cardiovascular benefit
Both tirzepatide and Semaglutide GLP-1 offer benefits beyond weight loss
Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market